Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutan...
FDA Drug Recall #D-0058-2023 — Class I — October 7, 2022
Recall Summary
| Recall Number | D-0058-2023 |
| Classification | Class I — Serious risk |
| Date Initiated | October 7, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Viatris Inc |
| Location | Canonsburg, PA |
| Product Type | Drugs |
| Quantity | 22400 syringes |
Product Description
Octreotide Acetate Injection 500 mcg/mL, 10 x 1 mL Single-Dose Unit-of-Use Syringes, For Subcutaneous or Intravenous Use, Rx Only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505 U.S.A., Made in Italy, NDC: 67457-246-00 (syringe), 67457-246-01 (carton).
Reason for Recall
Presence of Particulate Matter: Product complaint for the presence of glass particles in a syringe.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot #: AJ21002, Exp. 03/2024
Other Recalls from Viatris Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0204-2025 | Class II | Cardura XL (doxazosin) extended release tablets... | Dec 23, 2024 |
| D-0203-2025 | Class II | Cardura XL (doxazosin) extended release tablets... | Dec 23, 2024 |
| D-0123-2025 | Class II | Levothyroxine Sodium Tablets USP, 25 mcg, packa... | Nov 18, 2024 |
| D-0118-2025 | Class II | Levothyroxine Sodium Tablets USP, 125 mcg, pack... | Nov 18, 2024 |
| D-0122-2025 | Class II | Levothyroxine Sodium Tablets USP, 200 mcg, pack... | Nov 18, 2024 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.